Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ZLTQ's Cash-to-Debt is ranked higher than
82% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. NAS:ZLTQ: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ZLTQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 228.04 Max: No Debt
Current: No Debt
Equity-to-Asset 0.64
NAS:ZLTQ's Equity-to-Asset is ranked higher than
54% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. NAS:ZLTQ: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ZLTQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.69  Med: 0.69 Max: 0.89
Current: 0.64
-9.69
0.89
Interest Coverage 236.14
NAS:ZLTQ's Interest Coverage is ranked higher than
60% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. NAS:ZLTQ: 236.14 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ZLTQ' s Interest Coverage Range Over the Past 10 Years
Min: 236.14  Med: N/A Max: No Debt
Current: 236.14
Piotroski F-Score: 4
Altman Z-Score: 19.37
Beneish M-Score: -2.52
WACC vs ROIC
11.61%
-3.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 3.73
NAS:ZLTQ's Operating Margin % is ranked higher than
52% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. NAS:ZLTQ: 3.73 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ZLTQ' s Operating Margin % Range Over the Past 10 Years
Min: -1082.23  Med: -15.05 Max: 3.73
Current: 3.73
-1082.23
3.73
Net Margin % 0.20
NAS:ZLTQ's Net Margin % is ranked lower than
54% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. NAS:ZLTQ: 0.20 )
Ranked among companies with meaningful Net Margin % only.
NAS:ZLTQ' s Net Margin % Range Over the Past 10 Years
Min: -1111.78  Med: -15.69 Max: 16.37
Current: 0.2
-1111.78
16.37
ROE % 0.57
NAS:ZLTQ's ROE % is ranked lower than
55% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. NAS:ZLTQ: 0.57 )
Ranked among companies with meaningful ROE % only.
NAS:ZLTQ' s ROE % Range Over the Past 10 Years
Min: -299.73  Med: -14.02 Max: 42.91
Current: 0.57
-299.73
42.91
ROA % 0.37
NAS:ZLTQ's ROA % is ranked higher than
50% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. NAS:ZLTQ: 0.37 )
Ranked among companies with meaningful ROA % only.
NAS:ZLTQ' s ROA % Range Over the Past 10 Years
Min: -254.68  Med: -18.49 Max: 29.57
Current: 0.37
-254.68
29.57
ROC (Joel Greenblatt) % 45.69
NAS:ZLTQ's ROC (Joel Greenblatt) % is ranked higher than
84% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. NAS:ZLTQ: 45.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ZLTQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1427.33  Med: -489.02 Max: 45.69
Current: 45.69
-1427.33
45.69
3-Year Revenue Growth Rate 40.50
NAS:ZLTQ's 3-Year Revenue Growth Rate is ranked higher than
97% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. NAS:ZLTQ: 40.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ZLTQ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -22.3 Max: 41.9
Current: 40.5
-68.6
41.9
GuruFocus has detected 4 Warning Signs with ZELTIQ Aesthetics Inc $NAS:ZLTQ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ZLTQ's 10-Y Financials

Financials (Next Earnings Date: 2017-04-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ZLTQ Guru Trades in Q1 2016

Columbia Wanger 726,246 sh (New)
Jim Simons 594,400 sh (+472.36%)
Paul Tudor Jones Sold Out
Steven Cohen 1,698,300 sh (-26.79%)
RS Investment Management 781,322 sh (-33.90%)
» More
Q2 2016

ZLTQ Guru Trades in Q2 2016

Chuck Royce 81,000 sh (New)
RS Investment Management 1,056,821 sh (+35.26%)
Steven Cohen 2,219,762 sh (+30.70%)
Columbia Wanger 533,203 sh (-26.58%)
Jim Simons 45,910 sh (-92.28%)
» More
Q3 2016

ZLTQ Guru Trades in Q3 2016

Paul Tudor Jones 5,947 sh (New)
Jim Simons 161,600 sh (+251.99%)
Chuck Royce 108,000 sh (+33.33%)
Columbia Wanger 412,602 sh (-22.62%)
Steven Cohen 797,696 sh (-64.06%)
» More
Q4 2016

ZLTQ Guru Trades in Q4 2016

Joel Greenblatt 21,960 sh (New)
Paul Tudor Jones 31,742 sh (+433.75%)
Jim Simons 372,100 sh (+130.26%)
Chuck Royce 125,000 sh (+15.74%)
Columbia Wanger 248,042 sh (-39.88%)
Steven Cohen 125,506 sh (-84.27%)
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare: » details
ZELTIQ Aesthetics Inc is a medical technology company. The Company is engaged in developing and commercializing products utilizing its proprietary controlled cooling technology platform.

ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.

Ratios

vs
industry
vs
history
PE Ratio 5575.94
ZLTQ's PE Ratio is ranked lower than
100% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 26.64 vs. ZLTQ: 5575.94 )
Ranked among companies with meaningful PE Ratio only.
ZLTQ' s PE Ratio Range Over the Past 10 Years
Min: 1.09  Med: 54.69 Max: 5589
Current: 5575.94
1.09
5589
Forward PE Ratio 175.44
ZLTQ's Forward PE Ratio is ranked lower than
96% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.98 vs. ZLTQ: 175.44 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 5575.94
ZLTQ's PE Ratio without NRI is ranked lower than
100% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. ZLTQ: 5575.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZLTQ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.09  Med: 54.69 Max: 5589
Current: 5575.94
1.09
5589
PB Ratio 16.22
ZLTQ's PB Ratio is ranked lower than
97% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. ZLTQ: 16.22 )
Ranked among companies with meaningful PB Ratio only.
ZLTQ' s PB Ratio Range Over the Past 10 Years
Min: 1.79  Med: 9.98 Max: 19.15
Current: 16.22
1.79
19.15
PS Ratio 6.39
ZLTQ's PS Ratio is ranked lower than
74% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. ZLTQ: 6.39 )
Ranked among companies with meaningful PS Ratio only.
ZLTQ' s PS Ratio Range Over the Past 10 Years
Min: 0.16  Med: 4.53 Max: 7.94
Current: 6.39
0.16
7.94
Price-to-Free-Cash-Flow 248.95
ZLTQ's Price-to-Free-Cash-Flow is ranked lower than
94% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. ZLTQ: 248.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZLTQ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 82.3  Med: 197.22 Max: 4204.44
Current: 248.95
82.3
4204.44
Price-to-Operating-Cash-Flow 139.72
ZLTQ's Price-to-Operating-Cash-Flow is ranked lower than
97% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. ZLTQ: 139.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZLTQ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 58.67  Med: 129.18 Max: 245.71
Current: 139.72
58.67
245.71
EV-to-EBIT 165.90
ZLTQ's EV-to-EBIT is ranked lower than
98% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. ZLTQ: 165.90 )
Ranked among companies with meaningful EV-to-EBIT only.
ZLTQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -1381.5  Med: -5.3 Max: 644.5
Current: 165.9
-1381.5
644.5
EV-to-EBITDA 130.19
ZLTQ's EV-to-EBITDA is ranked lower than
95% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. ZLTQ: 130.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZLTQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -372.2  Med: -4.7 Max: 877.6
Current: 130.19
-372.2
877.6
Current Ratio 2.27
ZLTQ's Current Ratio is ranked lower than
51% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. ZLTQ: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ZLTQ' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.48 Max: 8.23
Current: 2.27
0.63
8.23
Quick Ratio 1.75
ZLTQ's Quick Ratio is ranked higher than
54% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ZLTQ: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
ZLTQ' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.01 Max: 7.85
Current: 1.75
0.52
7.85
Days Inventory 112.10
ZLTQ's Days Inventory is ranked higher than
58% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. ZLTQ: 112.10 )
Ranked among companies with meaningful Days Inventory only.
ZLTQ' s Days Inventory Range Over the Past 10 Years
Min: 46.43  Med: 104.98 Max: 163.22
Current: 112.1
46.43
163.22
Days Sales Outstanding 56.95
ZLTQ's Days Sales Outstanding is ranked higher than
66% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. ZLTQ: 56.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZLTQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.79  Med: 39.55 Max: 237.12
Current: 56.95
8.79
237.12
Days Payable 59.71
ZLTQ's Days Payable is ranked higher than
52% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ZLTQ: 59.71 )
Ranked among companies with meaningful Days Payable only.
ZLTQ' s Days Payable Range Over the Past 10 Years
Min: 42.46  Med: 58.25 Max: 144.83
Current: 59.71
42.46
144.83

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
ZLTQ's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. ZLTQ: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZLTQ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -453  Med: -3.9 Max: -2.7
Current: -2.7
-453
-2.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 25.27
ZLTQ's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. ZLTQ: 25.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ZLTQ' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.36  Med: 16.59 Max: 25.3
Current: 25.27
3.36
25.3
Price-to-Tangible-Book 16.82
ZLTQ's Price-to-Tangible-Book is ranked lower than
89% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. ZLTQ: 16.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ZLTQ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.54  Med: 11.12 Max: 16.84
Current: 16.82
2.54
16.84
Price-to-Intrinsic-Value-Projected-FCF 53.69
ZLTQ's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ZLTQ: 53.69 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZLTQ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 41.85  Med: 224.71 Max: 407.57
Current: 53.69
41.85
407.57
Price-to-Median-PS-Value 1.41
ZLTQ's Price-to-Median-PS-Value is ranked lower than
73% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ZLTQ: 1.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZLTQ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.05 Max: 1.42
Current: 1.41
0.08
1.42
Price-to-Graham-Number 64.93
ZLTQ's Price-to-Graham-Number is ranked lower than
100% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ZLTQ: 64.93 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ZLTQ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.42  Med: 22.51 Max: 65.02
Current: 64.93
3.42
65.02
Earnings Yield (Greenblatt) % 0.61
ZLTQ's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ZLTQ: 0.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZLTQ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 0.5 Max: 299
Current: 0.61
0.2
299

More Statistics

Revenue (TTM) (Mil) $354.2
EPS (TTM) $ 0.01
Beta1.20
Short Percentage of Float8.15%
52-Week Range $23.58 - 56.18
Shares Outstanding (Mil)40.42

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 421 490
EPS ($) 0.32 0.88
EPS without NRI ($) 0.32 0.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
Steven Cohen's Newest Buys, Additions and Reductions Mar 04 2015 
Steven Cohen Buys New Drug Stock, Triples Investment in Medical Company Jan 25 2015 
4 Stocks To Buy, 1 To Avoid In 2012 Feb 18 2012 
Weekly CFO Sales Highlight: INFA, DHR, AN, SMTC, ZLTQ Oct 31 2011 

More From Other Websites
Lifshitz & Miller LLP Announces Investigation of Delta Natural Gas Company, Inc., DigitalGlobe,... Mar 24 2017
ZELTIQ AESTHETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Mar 15 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of ZELTIQ... Mar 13 2017
ZELTIQ AESTHETICS (ZLTQ) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating ZELTIQ... Mar 13 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of ZELTIQ Aesthetics, Inc.... Mar 09 2017
ZELTIQ AESTHETICS INC Financials Mar 07 2017
ZELTIQ Aesthetics, Inc. :ZLTQ-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
ZELTIQ® Showcases CoolAdvantage Petite™ Applicator for the CoolSculpting® System at American... Mar 03 2017
Zeltiq beats Street 4Q forecasts Mar 01 2017
Zeltiq beats Street 4Q forecasts Mar 01 2017
ZELTIQ AESTHETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 01 2017
ZELTIQ Announces Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
[$$] Gormley's Take: Body Beautification Is Sexy Business Feb 22 2017
Medtronic Earnings Rebound in Third Quarter, Shares Climb Feb 21 2017
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of... Feb 17 2017
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ZELTIQ Aesthetics,... Feb 16 2017
ZELTIQ AESTHETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Feb 15 2017
ZELTIQ INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... Feb 15 2017
WEISSLAW LLP: ZELTIQ Aesthetics, Inc. Acquisition May Not Be in the Best Interests of ZLTQ... Feb 14 2017
ZELTIQ AESTHETICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the... Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)